Cardiac Toxicity, HER2-positive Breast Cancer, High Altitude, Targeted Therapy
Conditions
Keywords
HER2-positive breast cancer, Targeted therapy, Cardiotoxicity, High Altitude
Brief summary
This is a prospective, multicenter, cohort study aiming to explore the cardiotoxicity of targeted therapy for HER-2 positive breast cancer patients who lives in high altitude area. One hundred and thirty two HER-2 positive breast cancer patients who will receive neoadjuvant, adjuvant, or palliative targeted therapy will be enrolled. The cardiotoxicity of targeted therapy will be observed and recorded during the treatment and one year after the end of treatment. The subjects will be stratified by age, baseline cardiac risk factors, and anthracyclines.
Detailed description
HER-2 positive breast cancer patients who live at high altitudes greater than 2000 meters for long periods of time and will receive trastuzumab-based targeted therapy will be enrolled. The subjects included early and advanced patients. Treatment regimens includes chemotherapy combined with trastuzumab, chemotherapy combined with trastuzumab and pertuzumab, trastuzumab alone, and trastuzumab plus pertuzumab. Electrocardiogram, cardiac ultrasound, NT-proBNP, and TNI will be tested every 3 months when the treatment begins. The primary endpoint is cardiotoxity. The second endpoints is pathologic complete response (pCR) rate in neoadjuvant therapy, objective remission rate (ORR) and disease control rate (DCR) in neoadjuvant and palliative therapy.
Interventions
OTHERHigh altitude
High altitude is defined as \>2000m.
Sponsors
Affiliated Hospital of Qinghai University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed invasive HER2-positive breast cancer. 2. The baseline left ventricular ejection fraction \>55%. 3. Living at high altitude area （\>2000 meters）for at least 10 years. 4. ECOG score 0-2. 5. Expected survival time ≥ 12 months.
Exclusion criteria
1. Patients with previous breast cancer or other malignant tumor within 5 years. 2. Patients who had accepted previous anti-HER2 or anthracyclines-based therapy. 3. Patients with severe heart disease or discomfort. 4. Patients who are pregnant. 5. Patients with other conditions considered not suitable to be enrolled by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence rate of cardiotoxicity | 5 years | Cardiotoxicity includes death from cardiac cause, severe congestive heart failure (New York Heart Association Class III or IV), more than 10% decrease of left ventricular ejection fraction (LVEF) and to below 50%, and an asymptomatic or mildly symptomatic (NYHA class II) substantial decrease in LVEF. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 5 years | Overall survival of the enrolled patients |
| pCR rate | 4 years | Pathologic complete response (pCR) rate in patients received neoadjuvant therapy |
| ORR | 4 years | Objective remission rate in patients received neoadjuvant and palliative therapy |
| DCR | 4 years | Disease control rate in patients received neoadjuvant and palliative therapy |
| the incidence of treatment-related adverse events | 5 years | Incidence and Severity of adverse events according to the CTC AE V4.03 Incidence and Severity of adverse events according to the CTC AE V4.03 Incidence and severity of adverse events according to the CTC AE V4.03 |
Countries
China
Outcome results
None listed